迪哲医药：预计2025年度净亏损7.7亿元左右

Group 1 - The company expects to achieve an operating revenue of approximately 800 million yuan in 2025, an increase of about 440.1 million yuan compared to the previous year, representing a year-on-year growth of approximately 122.28% [1] - The estimated R&D expenses for 2025 are around 860 million yuan, which is an increase of about 136.31 million yuan from the previous year, reflecting a year-on-year increase of approximately 18.84% [1] - The projected net loss attributable to the parent company's owners for 2025 is approximately 770 million yuan, a reduction of about 75.96 million yuan compared to the previous year, indicating a year-on-year decrease in loss of approximately 8.98% [1] - The estimated net loss attributable to the parent company's owners, excluding non-recurring gains and losses, is around 850 million yuan for 2025, which is a decrease of about 48.89 million yuan from the previous year, showing a year-on-year reduction in loss of approximately 5.44% [1]